Exane Asset Management boosted its position in shares of CytomX Therapeutics Inc (NASDAQ:CTMX) by 79.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 50,000 shares of the biotechnology company’s stock after acquiring an additional 22,100 shares during the quarter. Exane Asset Management’s holdings in CytomX Therapeutics were worth $755,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of CTMX. Legal & General Group Plc raised its holdings in CytomX Therapeutics by 15.3% during the 3rd quarter. Legal & General Group Plc now owns 7,036 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 934 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in CytomX Therapeutics during the 3rd quarter valued at $225,000. State Board of Administration of Florida Retirement System raised its holdings in CytomX Therapeutics by 18.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 15,904 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 2,478 shares during the last quarter. Verition Fund Management LLC bought a new stake in CytomX Therapeutics during the 3rd quarter valued at $259,000. Finally, Assenagon Asset Management S.A. bought a new stake in CytomX Therapeutics during the 3rd quarter valued at $363,000. Institutional investors own 83.93% of the company’s stock.
Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Tuesday, January 8th. BidaskClub upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. ValuEngine lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Goldman Sachs Group upgraded shares of CytomX Therapeutics from a “neutral” rating to a “buy” rating in a report on Thursday, December 13th. Finally, Piper Jaffray Companies assumed coverage on shares of CytomX Therapeutics in a report on Sunday, December 2nd. They issued an “overweight” rating and a $13.24 price objective for the company. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $30.41.
NASDAQ:CTMX opened at $19.06 on Monday. The stock has a market capitalization of $857.84 million, a PE ratio of -16.43 and a beta of 0.91. CytomX Therapeutics Inc has a 1-year low of $12.51 and a 1-year high of $35.00.
In other news, CFO Debanjan Ray sold 3,000 shares of the company’s stock in a transaction dated Wednesday, December 12th. The shares were sold at an average price of $15.00, for a total value of $45,000.00. Following the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at approximately $133,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 8.50% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “CytomX Therapeutics Inc (CTMX) Position Raised by Exane Asset Management” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2019/02/11/cytomx-therapeutics-inc-ctmx-position-raised-by-exane-asset-management.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Story: Why is the conference call important?
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.